Methyl jasmonate: Putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis

International Journal of Cell Biology

Volumn , Issue , 2014, Pages

  Cesari, Italo Mario ^a   Carvalho, Erika ^a   Figueiredo Rodrigues, Mariana ^a   Mendonça, Bruna Dos Santos ^a   Amôedo, Nivea Dias ^a   Rumjanek, Franklin David ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATE; ALDO KETO REDUCTASE 1; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; CYTOCHROME C; HEXOKINASE; JASMONIC ACID METHYL ESTER; OXIDOREDUCTASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; LEUKEMIA CELL; METASTASIS INHIBITION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

EID: 84896852880     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2014/572097     Document Type: Review

References (256)

1. Ertel A., Verghese A., Byers S. W., Ochs M., Tozeren A., Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Molecular Cancer 2006 5, article 55 2-s2.0-33750996156 10.1186/1476-4598-5-55
2. Mou X., Kesari S., Wen P. Y., Huang X., Crude drugs as anticancer agents. International Journal of Clinical and Experimental Medicine 2011 4 1 17 25 2-s2.0-79951718931
3. Liechti R., Farmer E. E., The Jasmonate pathway. Science 2002 296 5573 1649 1650 2-s2.0-0037204996 10.1126/science.1071547
4. Weber H., Fatty acid-derived signals in plants. Trends in Plant Science 2002 7 5 217 224 2-s2.0-0036581314 10.1016/S1360-1385(02)02250-1
5. Christie W. W., Plant oxylipins: chemistry and biology. 2010, http://lipidlibrary.aocs.org/lipids/eicplant/index.htm
6. Sembdner G., Parthier B., The biochemistry and the physiological and molecular actions of jasmonates. Annual Review of Plant Physiology and Plant Molecular Biology 1993 44 1 569 589 2-s2.0-0001596943
7. Vasyukova N. I., Zinovieva S. V., Udalova Z. V., Gerasimova N. G., Ozeretskovskaya O. L., Sonin M. D., Jasmonic acid and tomato resistance to the root-knot nematode Meloidogyne incognita. Doklady Biological Sciences 2009 428 448 450 2-s2.0-75649115410
8. Farmer E. E., Ryan C. A., Interplant communication: airborne methyl jasmonate induces synthesis of proteinase inhibitors in plant leaves. Proceedings of the National Academy of Sciences of the United States of America 1990 87 19 7713 7716 2-s2.0-0025009188
9. De Vos M., Van Oosten V. R., Van Poecke R. M. P., Van Pelt J. A., Pozo M. J., Mueller M. J., Buchala A. J., Métraux J.-P., Van Loon L. C., Dicke M., Pieterse C. M. J., Signal signature and transcriptome changes of Arabidopsis during pathogen and insect attack. Molecular Plant-Microbe Interactions 2005 18 9 923 937 2-s2.0-23844457959 10.1094/MPMI-18-0923
10. Izaguirre M. M., Mazza C. A., Svatoš A., Baldwin I. T., Ballaré C. L., Solar ultraviolet-B radiation and insect herbivory trigger partially overlapping phenolic responses in Nicotiana attenuata and Nicotiana longiflora. Annals of Botany 2007 99 1 103 109 2-s2.0-33847749731 10.1093/aob/mcl226
11. Karban R., Plant behaviour and communication. Ecology Letters 2008 11 7 727 739 2-s2.0-44649189101 10.1111/j.1461-0248.2008.01183.x
12. 2 in Ricinus communis leaves. Brazilian Journal of Plant Physiology 2010 22 3 151 158 2-s2.0-79951793358
13. A.-H.-Mackerness S., Surplus S. L., Blake P., John C. F., Buchanan-Wollaston V., Jordan B. R., Thomas B., Ultraviolet-B-induced stress and changes in gene expression in Arabidopsis thaliana: role of signalling pathways controlled by jasmonic acid, ethylene and reactive oxygen species. Plant, Cell & Environment 1999 22 11 1413 1423 2-s2.0-0032709341 10.1046/j.1365-3040. 1999.00499.x
14. Zhang L., Xing D., Methyl jasmonate induces production of reactive oxygen species and alterations in mitochondrial dynamics that precede photosynthetic dysfunction and subsequent cell death. Plant and Cell Physiology 2008 49 7 1092 1111 2-s2.0-47249114779 10.1093/pcp/pcn086
15. Fingrut O., Flescher E., Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002 16 4 608 616 2-s2.0-0036240569 10.1038/sj/leu/2402419
16. Flescher E., Jasmonates-a new family of anti-cancer agents. Anti-Cancer Drugs 2005 16 9 911 916 2-s2.0-26244458767 10.1097/01.cad.0000176501.63680.80
17. Fingrut O., Reischer D., Rotem R., Goldin N., Altboum I., Zan-Bar I., Flescher E., Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. British Journal of Pharmacology 2005 146 6 800 808 2-s2.0-27744487132 10.1038/sj.bjp.0706394
18. Rotem R., Fingrut O., Moskovitz J., Flescher E., The anticancer plant stress-protein methyl jasmonate induces activation of stress-regulated c-Jun N-terminal kinase and p38 protein kinase in human lymphoid cells. Leukemia 2003 17 11 2230 2234 2-s2.0-0242558937 10.1038/sj.leu.2403107
19. Flescher E., Jasmonates in cancer therapy. Cancer Letters 2007 245 1-2 1 10 2-s2.0-33845642967 10.1016/j.canlet.2006.03.001
20. Goldin N., Heyfets A., Reischer D., Flescher E., Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family. Journal of Bioenergetics and Biomembranes 2007 39 1 51 57 2-s2.0-34249934157 10.1007/s10863-006-9061-y
21. Cohen S., Flescher E., Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry 2009 70 13-14 1600 1609 2-s2.0-70350517590 10.1016/j.phytochem.2009.06.007
22. Reischer-Pelech D., Flescher E., Jasmonates: plant stress hormones as anticancer agents. Emerging Trends in Dietary Components for Preventing and Combating Disease 2012 303 322
23. Elia U., Flescher E., Combined chemotherapy or biotherapy with jasmonates: targeting energy metabolism for cancer treatment. Current Pharmaceutical Biotechnology 2013 14 3 331 341
24. Raviv Z., Cohen S., Reischer-Pelech D., The anti-cancer activities of jasmonates. Cancer Chemotherapy and Pharmacology 2013 71 2 275 285
25. Yeruva L., Elegbede J. A., Carper S. W., Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells. Anti-Cancer Drugs 2008 19 8 766 776 2-s2.0-53749090929 10.1097/CAD.0b013e32830b5894
26. Kniazhanski T., Jackman A., Heyfets A., Gonen P., Flescher E., Sherman L., Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells. Cancer Letters 2008 271 1 34 46 2-s2.0-53049089458 10.1016/j.canlet.2008.05.031
27. Zhao J., Kang S., Zhang X., You S., Park J.-S., Jung J. H., Kim D.-K., Apoptotic activity of a new jasmonate analogue is associated with its induction of DNA damage. Oncology Reports 2010 24 3 771 777 2-s2.0-77956307170 10.3892/or-00000920
28. Milrot E., Jackman A., Kniazhanski T., Gonen P., Flescher E., Sherman L., Methyl jasmonate reduces the survival of cervical cancer cells and downregulates HPV E6 and E7, and survivin. Cancer Letters 2012 319 1 31 38 2-s2.0-84858071650 10.1016/j.canlet.2011.12.028
29. Milrot E., Jackman A., Flescher E., Gonen P., Kelson I., Keisari Y., Sherman L., Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation. Investigational New Drugs 2013 31 2 333 344
30. Goldin N., Arzoine L., Heyfets A., Israelson A., Zaslavsky Z., Bravman T., Bronner V., Notcovich A., Shoshan-Barmatz V., Flescher E., Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008 27 34 4636 4643 2-s2.0-47749093652 10.1038/onc.2008.108
31. Ávila-Román J., Talero E., de los Reyes Jiménez C., Methyl jasmonate is a promising tool against colon cáncer. Proceedings of the 6th European Congress of Pharmacology 2012
32. Raviv Z., Zilberberg A., Cohen S., Reischer-Pelech D., Horrix C., Berger M. R., Rosin-Arbesfeld R., Flescher E., Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. British Journal of Pharmacology 2011 164 5 1433 1444 2-s2.0-80054022978 10.1111/j.1476-5381.2011.01419.x
33. Zheng L., Li D., Xiang X., Tong L., Qi M., Pu J., Huang K., Tong Q., Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14. BMC Cancer 2013 13, article 74
34. Park C., Jin C.-Y., Kim G.-Y., Cheong J., Jung J. H., Yoo Y. H., Choi Y. H., A methyl jasmonate derivative, J-7, induces apoptosis in human hepatocarcinoma Hep3B cells in vitro. Toxicology in Vitro 2010 24 7 1920 1926 2-s2.0-77957018959 10.1016/j.tiv.2010.08.001
35. Park C., Jin C.-Y., Hwang H. J., Kim G.-Y., Jung J. H., Kim W.-J., Yoo Y. H., Choi Y. H., J7, a methyl jasmonate derivative, enhances TRAIL-mediated apoptosis through up-regulation of reactive oxygen species generation in human hepatoma HepG2 cells. Toxicology in Vitro 2012 26 1 86 93 2-s2.0-84855353202 10.1016/j.tiv.2011.10.016
36. Kim J. H., Lee S. Y., Oh S. Y., Han S. I., Park H. G., Yoo M.-A., Kang H. S., Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells. Oncology Reports 2004 12 6 1233 1238 2-s2.0-16644392664
37. Yeruva L., Pierre K. J., Carper S. W., Elegbede J. A., Toy B. J., Wang R. C., Jasmonates induce apoptosis and cell cycle arrest in non-small cell lung cancer lines. Experimental Lung Research 2006 32 10 499 516 2-s2.0-33845796924 10.1080/01902140601059604
38. Rotem R., Heyfets A., Fingrut O., Blickstein D., Shaklai M., Flescher E., Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Research 2005 65 5 1984 1993 2-s2.0-16444376422 10.1158/0008-5472.CAN-04-3091
39. Reischer D., Heyfets A., Shimony S., Nordenberg J., Kashman Y., Flescher E., Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. British Journal of Pharmacology 2007 150 6 738 749 2-s2.0-33947320591 10.1038/sj.bjp.0707146
40. Pereira Lopes J. E. F., Barbosa M. R., Stella C. N., Santos W. A., Pereira E. M., Nogueira-Neto J., Augusto E. M., Silva L. V., Smaili S. S., Gomes L. F., In vivo anti-angiogenic effects further support the promise of the antineoplasic activity of methyl jasmonate. Brazilian Journal of Biology 2010 70 2 443 449 2-s2.0-77954180925
41. Ishii Y., Kiyota H., Sakai S., Honma Y., Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia 2004 18 8 1413 1419 2-s2.0-4344686851 10.1038/sj.leu.2403421
42. Tsumura H., Akimoto M., Kiyota H., Ishii Y., Ishikura H., Honma Y., Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture. Leukemia 2009 23 4 753 760 2-s2.0-64849100788 10.1038/leu.2008.347
43. Jiang G.-S., Tong Q.-S., Zeng F.-Q., Hu B., Zheng L.-D., Cai J.-B., Liu Y., Methyl jasmonate induces apoptosis of human neuroblastoma cell line BE(2)-C and its mechanism. Yaoxue Xuebao 2008 43 6 584 590 2-s2.0-49049118474
44. Tong Q.-S., Jiang G.-S., Zheng L.-D., Tang S.-T., Cai J.-B., Liu Y., Zeng F.-Q., Dong J.-H., Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms. Acta Pharmacologica Sinica 2008 29 7 861 869 2-s2.0-65849284657 10.1111/j.1745-7254. 2008.00814.x
45. Tong Q.-S., Jiang G.-S., Zheng L.-D., Tang S.-T., Cai J.-B., Liu Y., Zeng F.-Q., Dong J.-H., Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines. Anti-Cancer Drugs 2008 19 6 573 581 2-s2.0-53749096199 10.1097/CAD. 0b013e3282fc46b0
46. Samaila D., Ezekwudo D. E., Yimam K. K., Elegbede J. A., Bioactive plant compounds inhibited the proliferation and induced apoptosis in human cancer cell lines, in vitro. Transactions of the Integrated Bio-Medical Informatics & Enabling Technologies Symposiums 2004 1 34 42
47. Ezekwudo D. E., Wang R. C., Elegbede J. A., Methyl jasmonate induced apoptosis in human prostate carcinoma cells via 5-lipoxygenase dependent pathway. Journal of Experimental Therapeutics and Oncology 2007 6 4 267 277 2-s2.0-36148943488
48. Yeruva L., Pierre K. J., Bathina M., Elegbede A., Carper S. W., Delayed cytotoxic effects of methyl jasmonate and cis-jasmone induced apoptosis in prostate cancer cells. Cancer Investigation 2008 26 9 890 899 2-s2.0-57049178439 10.1080/07357900801975272
49. Elia U., Flescher E., PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia 2008 10 11 1303 1313 2-s2.0-55849112650 10.1593/neo.08636
50. Scognamiglio J., Jones L., Letizia C. S., Api A. M., Fragrance material review on methyl jasmonate. Food and Chemical Toxicology 2012 50 supplement 3 S572 S576 2-s2.0-84860596188 10.1016/j.fct.2012.03.035
51. Palmieri B., Iannitti T., Capone S., Flescher E., A preliminary study of the local treatment of preneoplastic and malignant skin lesions using methyl jasmonate. European Review for Medical and Pharmacological Sciences 2011 15 3 333 336 2-s2.0-79957990169
52. Environmental Protection Agency (EPA), Methyl Jasmonate: exemption from the requirement of a tolerance. Federal Register 2013 78 74 22789 22794
53. Pietenpol J. A., Stewart Z. A., Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002 181-182 475 481 2-s2.0-18144434267 10.1016/S0300-483X(02)00460-2
54. van den Heuvel S., Cell-cycle regulation. WormBook 2005 The C. elegans Research Community, WormBook 10.1895/wormbook.1.28.1
55. Vermeulen K., Berneman Z. N., Van Bockstaele D. R., Cell cycle and apoptosis. Cell Proliferation 2003 36 3 165 175 2-s2.0-0038052800 10.1046/j.1365-2184.2003.00267.x
56. Reisman D., Takahashi P., Polson A., Boggs K., Transcriptional regulation of the p53 tumor suppressor gene in S-phase of the cell-cycle and the cellular response to DNA damage. Biochemistry Research International 2012 2012 5 808934 10.1155/2012/808934
57. Verbon E. H., Post J. A., Boonstra J., The influence of reactive oxygen species on cell cycle progression in mammalian cells. Gene 2012 511 1 1 6
58. Watson J., Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biology 2013 3 1 120144
59. Soucek L., Whitfield J., Martins C. P., Finch A. J., Murphy D. J., Sodir N. M., Karnezis A. N., Swigart L. B., Nasi S., Evan G. I., Modelling Myc inhibition as a cancer therapy. Nature 2008 455 7213 679 683 2-s2.0-53349103292 10.1038/nature07260
60. Jain A. K., Allton K., Iacovino M., Mahen E., Milczarek R. J., Zwaka T. P., Kyba M., Barton M. C., P53 regulates cell cycle and micrornas to promote differentiation of human embryonic stem cells. PLoS Biology 2012 10 2 2-s2.0-84857483281 10.1371/journal.pbio.1001268 e1001268
61. Chorawala M. R., Oza P. M., Shah G. B., Mechanisms of anticancer drugs resistance: an overview. International Journal of Pharmaceutical Sciences and Drug Research 2012 4 1 1 9
62. Suh Y.-A., Post S. M., Elizondo-Fraire A. C., Maccio D. R., Jackson J. G., El-Naggar A. K., Van Pelt C., Terzian T., Lozano G., Multiple stress signals activate mutant p53 in vivo. Cancer Research 2011 71 23 7168 7175 2-s2.0-82655181478 10.1158/0008-5472.CAN-11-0459
63. Kuribayashi K., Finnberg N., Jeffers J. R., Zambetti G. P., El-Deiry W. S., The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle 2011 10 14 2380 2389 2-s2.0-79960454735 10.4161/cc.10.14.16588
64. Puzio-Kuter A. M., The role of p53 in metabolic regulation. Genes and Cancer 2011 2 4 385 391 2-s2.0-80053036165 10.1177/1947601911409738
65. Suzuki K., Matsubara H., Recent advances in p53 research and cancer treatment. Journal of Biomedicine and Biotechnology 2011 2011 7 2-s2.0-80052664208 10.1155/2011/978312 978312
66. Grossel M. J., Hinds P. W., From cell cycle to differentiation: an expanding role for Cdk6. Cell Cycle 2006 5 3 266 270 2-s2.0-32244441908
67. Jones R. G., Thompson C. B., Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes and Development 2009 23 5 537 548 2-s2.0-61849135453 10.1101/gad.1756509
68. Olivier M., Hollstein M., Hainaut P., TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology 2010 2 1 a001008 2-s2.0-77955363995 10.1101/cshperspect.a001008
69. Maillet A., Pervaiz S., Redox regulation of p53, redox effectors regulated by p53: a subtle balance. Antioxidants and Redox Signaling 2012 16 11 1285 1294 2-s2.0-84859855907 10.1089/ars.2011.4434
70. Sablina A. A., Budanov A. V., Ilyinskaya G. V., Agapova L. S., Kravchenko J. E., Chumakov P. M., The antioxidant function of the p53 tumor suppressor. Nature Medicine 2005 11 12 1306 1313 2-s2.0-28644447272 10.1038/nm1320
71. Gottlieb E., Vousden K. H., P53 regulation of metabolic pathways. Cold Spring Harbor Perspectives in Biology 2010 2 4 a001040 2-s2.0-77952192188 10.1101/cshperspect.a001040
72. Li P.-F., Dietz R., von Harsdorf R., P53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO Journal 1999 18 21 6027 6036 2-s2.0-0033229866 10.1093/emboj/18.21.6027
73. Liu B., P53 and reactive oxygen species: a convoluted story [M.S. thesis] 2007 University of Kentucky. http://uknowledge.uky.edu/gradschool-theses/450/
74. Rae J. M., Creighton C. J., Meck J. M., Haddad B. R., Johnson M. D., MDA-MB-435 cells are derived from M14 Melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Research and Treatment 2007 104 1 13 19 2-s2.0-34250869019 10.1007/s10549-006-9392-8
75. Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T., Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biology & Therapy 2008 7 5 699 708 2-s2.0-56149097419
76. Nejad E. S., Askari H., Soltani S., Regulatory TGACG-motif may elicit the secondary metabolite production through inhibition of active Cyclin-dependent kinase/Cyclin complex. Plant Omics Journal 2012 5 6 553 558
77. Pauwels L., Morreel K., De Witte E., Lammertyn F., Van Montagu M., Boerjan W., Inzé D., Goossens A., Mapping methyl jasmonate-mediated transcriptional reprogramming of metabolism and cell cycle progression in cultured Arabidopsis cells. Proceedings of the National Academy of Sciences of the United States of America 2008 105 4 1380 1385 2-s2.0-39549118900 10.1073/pnas.0711203105
78. Dang C. V., MYC on the path to cancer. Cell 2012 149 1 22 35 2-s2.0-84859171807 10.1016/j.cell.2012.03.003
79. Nestal de Moraes G., Silva K. L., Vasconcelos F. D. C., Maia R. C., Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncology Reports 2011 25 6 1613 1619 2-s2.0-79954462657 10.3892/or.2011.1224
80. Rahman A., Sultan T., Islam R., Apoptosis and cancer: insights molecular mechanisms and treatments. International Journal of Biomolecules & Biomedicine 2012 2 1 1 16
81. Suen D.-F., Norris K. L., Youle R. J., Mitochondrial dynamics and apoptosis. Genes and Development 2008 22 12 1577 1590 2-s2.0-45349094984 10.1101/gad.1658508
82. Kroemer G., Galluzzi L., Brenner C., Mitochondrial membrane permeabilization in cell death. Physiological Reviews 2007 87 1 99 163 2-s2.0-33845977959 10.1152/physrev.00013.2006
83. Bender T., Martinou G. C., Where killers meet-permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harbor Perspectives in Biology 2013 5 1 a011106
84. Kang M. H., Reynolds C. P., BcI-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 2009 15 4 1126 1132 2-s2.0-63149129655 10.1158/1078-0432.CCR-08-0144
85. Kumarswamy R., Chandna S., Putative partners in Bax mediated cytochrome-c release: ANT, CypD, VDAC or none of them? Mitochondrion 2009 9 1 1 8 2-s2.0-60249089101 10.1016/j.mito.2008.10.003
86. +-dependent cell survival and death. Molecular Cell 2009 33 3 377 388 2-s2.0-59649092928 10.1016/j.molcel.2009.01. 018
87. Shimizu S., Narita M., Tsujimoto Y., Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999 399 6735 483 487 2-s2.0-0033519705 10.1038/20959
88. Cheng E. H.-Y., Sheiko T. V., Fisher J. K., Craigen W. J., Korsmeyer S. J., VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003 301 5632 513 517 2-s2.0-0043204996 10.1126/science.1083995
89. Baines C. P., Kaiser R. A., Sheiko T., Craigen W. J., Molkentin J. D., Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nature Cell Biology 2007 9 5 550 555 2-s2.0-34247895697 10.1038/ncb1575
90. Kreuzaler P., Watson C. J., Killing a cancer: what are the alternatives? Nature Reviews Cancer 2012 12 6 411 424
91. Rivlin N., Brosh R., Oren M., Rotter V., Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes and Cancer 2011 2 4 466 474 2-s2.0-80053039210 10.1177/1947601911408889
92. Vousden K. H., Prives C., Blinded by the light: the growing complexity of p53. Cell 2009 137 3 413 431 2-s2.0-65349103899 10.1016/j.cell.2009.04.037
93. Wang H., Luo K., Tan L. Z., Ren B. G., Gu L. Q., Michalopoulos G., Luo J. H., Yu Y. P., P53-induced gene 3 mediates cell death induced by glutathione peroxidase 3. The Journal of Biological Chemistry 2012 287 20 16890 16902
94. Ozaki T., Nakagawara A., P53: the attractive tumor suppressor in the cancer research field. Journal of Biomedicine and Biotechnology 2011 2011 13 2-s2.0-79251534367 10.1155/2011/603925 603925
95. Kracikova M., Akiri G., George A., Sachidanandam R., Aaronson S. A., A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death & Differentiation 2013 20 4 576 588
96. Fulda S., Kroemer G., Mitochondria as therapeutic targets for the treatment of malignant disease. Antioxidants and Redox Signaling 2011 15 12 2937 2949 2-s2.0-80155167845 10.1089/ars.2011.4078
97. Honeychurch J., Alduaij W., Azizyan M., Cheadle E. J., Pelicano H., Ivanov A., Huang P., Cragg M. S., Illidge T. M., Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012 119 15 3523 3533 2-s2.0-84859833070 10.1182/blood-2011-12-395541
98. Lambeth J. D., NOX enzymes and the biology of reactive oxygen. Nature Reviews Immunology 2004 4 3 181 189 2-s2.0-1542406446
99. Deavall D. G., Martin E. A., Horner J. M., Roberts R., Drug-induced oxidative stress and toxicity. Journal of Toxicology 2012 2012 13 645460 10.1155/2012/645460
100. Verrax J., Dejeans N., Sid B., Glorieux C., Calderon P. B., Intracellular ATP levels determine cell death fate of cancer cells exposed to both standard and redox chemotherapeutic agents. Biochemical Pharmacology 2011 82 11 1540 1548 2-s2.0-80255125980 10.1016/j.bcp.2011.07.102
101. Festjens N., Vanden Berghe T., Vandenabeele P., Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochimica et Biophysica Acta 2006 1757 9-10 1371 1387 2-s2.0-33749178260 10.1016/j.bbabio.2006.06.014
102. Irrinki K. M., Mallilankaraman K., Thapa R. J., Chandramoorthy H. C., Smith F. J., Jog N. R., Gandhirajan R. K., Kelsen S. G., Houser S. R., May M. J., Balachandran S., Madesh M., Requirement of FADD, NEMO, and BAX/BAK for aberrant mitochondrial function in tumor necrosis factor alpha-induced necrosis. Molecular and Cellular Biology 2011 31 18 3745 3758 2-s2.0-80052583012 10.1128/MCB.05303-11
103. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular Cell Biology 2010 11 10 700 714 2-s2.0-77957105977 10.1038/nrm2970
104. Ezekwudo D., Shashidharamurthy R., Devineni D., Bozeman E., Palaniappan R., Selvaraj P., Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Letters 2008 270 2 277 285 2-s2.0-52449095786 10.1016/j.canlet.2008.05.022
105. Klippel S., Jakubikova J., Delmore J., Methyl jasmonate displays in vitro and in vivo activity against multiple myeloma cells. British Journal of Haematology 2012 159 3 340 351
106. Manda G., Nechifor M. T., Neagu T.-M., Reactive oxygen species, cancer and anti-cancer therapies. Current Chemical Biology 2009 3 1 22 46 2-s2.0-65549116046
107. Wolin M. S., Ahmad M., Gupte S. A., Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. American Journal of Physiology-Lung Cellular and Molecular Physiology 2005 289 2 L159 L173 2-s2.0-22444433668 10.1152/ajplung.00060.2005
108. Ushio-Fukai M., Localizing NADPH oxidase-derived ROS. Science's STKE 2006 2006 349, article re8 2-s2.0-33749047437 10.1126/stke.3492006re8
109. Chen K., Craige S. E., Keaney J. F. Jr., Downstream targets and intracellular compartmentalization in Nox signaling. Antioxidants & Redox Signaling 2009 11 10 2467 2480 2-s2.0-70349341899
110. Paulsen C. E., Carroll K. S., Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chemical Biology 2010 5 1 47 62 2-s2.0-75749123115 10.1021/cb900258z
111. Wejksza K., Lee-Chang C., Bodogai M., Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor alpha. The Journal of Immunology 2013 190 6 2575 2584
112. Lambert A. J., Brand M. D., Reactive oxygen species production by mitochondria. Methods in Molecular Biology 2009 554 165 181 2-s2.0-70349769764 10.1007/978-1-59745-521-3-11
113. Malinouski M., Zhou Y., Belousov V. V., Hatfield D. L., Gladyshev V. N., Hydrogen peroxide probes directed to different cellular compartments. PLoS ONE 2011 6 1 2-s2.0-79251603273 10.1371/journal.pone.0014564 e14564
114. Korshunov S. S., Skulachev V. P., Starkov A. A., High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Letters 1997 416 1 15 18 2-s2.0-0030729851 10.1016/S0014-5793(97)01159-9
115. Turrens J. F., Mitochondrial formation of reactive oxygen species. Journal of Physiology 2003 552 2 335 344 2-s2.0-0142150051 10.1113/jphysiol. 2003.049478
116. Le Bras M., Clément M.-V., Pervaiz S., Brenner C., Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histology and Histopathology 2005 20 1 205 219 2-s2.0-11144303507
117. Chatterjee A., Dasgupta S., Sidransky D., Mitochondrial subversion in cancer. Cancer Prevention Research 2011 4 5 638 654 2-s2.0-79955835149 10.1158/1940-6207.CAPR-10-0326
118. Ladiges W., Wanagat J., Preston B., Loeb L., Rabinovitch P., A mitochondrial view of aging, reactive oxygen species and metastatic cancer. Aging Cell 2010 9 4 462 465 2-s2.0-78049447695
119. Anso E., Mullen A. R., Felsher D. W., Matés J. M., DeBerardinis R. J., Chandel N. S., Metabolic changes in cancer cells upon suppression of MYC. Cancer & Metabolism 2013 1, article 7
120. Ralph S. J., Rodríguez-Enríquez S., Neuzil J., Saavedra E., Moreno-Sánchez R., The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Molecular Aspects of Medicine 2010 31 2 145 170 2-s2.0-77951432631 10.1016/j.mam.2010.02.008
121. Bechtel W., Bauer G., Catalase protects tumor cells from apoptosis induction by intercellular ROS signaling. Anticancer Research 2009 29 11 4541 4557 2-s2.0-75149195862
122. Ralph S. J., Rodríguez-Enríquez S., Neuzil J., Moreno-Sánchez R., Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Molecular Aspects of Medicine 2010 31 1 29 59 2-s2.0-77649183649 10.1016/j.mam.2009.12.006
123. Ozben T., Oxidative stress and apoptosis: impact on cancer therapy. Journal of Pharmaceutical Sciences 2007 96 9 2181 2196 2-s2.0-34748858784 10.1002/jps.20874
124. Maiti A. K., Reactive oxygen species reduction is a key underlying mechanism of drug resistance in cancer chemotherapy. Chemotherapy 2012 1 104 108
125. Loyola-Vargas V., Ruiz-May E., Galaz-Avalos R., De-la-Pena C., The role of jasmonic acid in root mitochondria disruption. Plant Signaling & Behavior 2012 7 6 611 614
126. Orozco-Cárdenas M. L., Narváez-Vásquez J., Ryan C. A., Hydrogen peroxide acts as a second messenger for the induction of defense genes in tomato plants in response to wounding, systemin, and methyl jasmonate. Plant Cell 2001 13 1 179 191 2-s2.0-0035101409 10.1105/tpc.13.1.179
127. Bienert G. P., Schjoerring J. K., Jahn T. P., Membrane transport of hydrogen peroxide. Biochimica et Biophysica Acta 2006 1758 8 994 1003 2-s2.0-33748564986 10.1016/j.bbamem.2006.02.015
128. Hung K. T., Hsu Y. T., Kao C. H., Hydrogen peroxide is involved in methyl jasmonate-induced senescence of rice leaves. Physiologia Plantarum 2006 127 2 293 303 2-s2.0-33744464485 10.1111/j.1399-3054.2006.00662.x
129. Küpper F. C., Gaquerel E., Cosse A., Adas F., Peters A. F., Müller D. G., Kloareg B., Salaün J.-P., Potin P., Free fatty acids and methyl jasmonate trigger defense reactions in laminaria digitata. Plant and Cell Physiology 2009 50 4 789 800 2-s2.0-65349095151 10.1093/pcp/pcp023
130. Oh S. Y., Kim J. H., Park M. J., Kim S. M., Yoon C. S., Joo Y. M., Park J. S., Han S. I., Park H. G., Kang H. S., Induction of heat shock protein 72 in C6 glioma cells by methyl jasmonate through ROS-dependent heat shock factor 1 activation. International Journal of Molecular Medicine 2005 16 5 833 839 2-s2.0-33644635986
131. m produced either by a closure of the mitochondrial permeability transition pore or by inhibition of the ATP synthase. Cancer Letts 2007 252 1 8
132. Davies N. J., Hayden R. E., Simpson P. J., Birtwistle J., Mayer K., Ride J. P., Bunce C. M., AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Cancer Research 2009 69 11 4769 4775 2-s2.0-66349108684 10.1158/0008-5472.CAN-08-4533
133. Fritz V., Fajas L., Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010 29 31 4369 4377 2-s2.0-77955470822 10.1038/onc.2010.182
134. Warburg O., On respiratory impairment in cancer cells. Science 1956 124 3215 269 270 2-s2.0-0001221508
135. Mathupala S. P., Ko Y. H., Pedersen P. L., The pivotal roles of mitochondria in cancer: warburg and beyond and encouraging prospects for effective therapies. Biochimica et Biophysica Acta 2010 1797 6-7 1225 1230 2-s2.0-77953812468 10.1016/j.bbabio.2010.03.025
136. Turcotte M. L., Parliament H., Franko A., Allalunis-Turner J., Variation in mitochondrial function in hypoxia-sensitive and hypoxia-tolerant human glioma cells. British Journal of Cancer 2002 86 4 619 624 2-s2.0-0037065972 10.1038/sj.bjc.6600087
137. Griguer C. E., Oliva C. R., Gillespie G. Y., Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. Journal of Neuro-Oncology 2005 74 2 123 133 2-s2.0-26944452745 10.1007/s11060-004-6404-6
138. Wolf A., Agnihotri S., Guha A., Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2010 1 7 552 562 2-s2.0-79958015593
139. Majeed R., Hamid A., Qurishi Y., Therapeutic targeting of cancer cell metabolism: role of metabolic enzymes, oncogenes and tumor suppressor genes. Journal of Cancer Science & Therapy 2012 4 9 281 291
140. Wilson J. E., Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. Journal of Experimental Biology 2003 206 12 2049 2057 2-s2.0-0038714272 10.1242/jeb.00241
141. John S., Weiss J. N., Ribalet B., Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS ONE 2011 6 3 2-s2.0-79952417296 10.1371/journal.pone.0017674 e17674
142. Mathupala S. P., Ko Y. H., Pedersen P. L., Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Seminars in Cancer Biology 2009 19 1 17 24 2-s2.0-60249083822 10.1016/j.semcancer.2008.11.006
143. Pedersen P. L., Mathupala S., Rempel A., Geschwind J. F., Ko Y. H., Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochimica
144. Nakashima R. A., Mangan P. S., Colombini M., Pedersen P. L., Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N′- dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry 1986 25 5 1015 1021 2-s2.0-0022595453
145. Pedersen P. L., Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer. Journal of Bioenergetics and Biomembranes 2008 40 3 123 126 2-s2.0-52449089360 10.1007/s10863-008-9165-7
146. Gonçalves R. P., Buzhysnskyy N., Scheuring S., Mini review on the structure and supramolecular assembly of VDAC. Journal of Bioenergetics and Biomembranes 2008 40 3 133 138 2-s2.0-52449086028 10.1007/s10863-008-9141-2
147. Shoshan-Barmatz V., Mizrachi D., VDAC1: from structure to cancer therapy. Frontiers in Oncology 2012 2, article 146
148. Grills C., Jithesh P. V., Blayney J., Zhang S.-D., Fennell D. A., Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS ONE 2011 6 1 2-s2.0-79551641146 10.1371/journal.pone.0014635 e14635
149. Galluzzi L., Kepp O., Tajeddine N., Kroemer G., Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene 2008 27 34 4633 4635 2-s2.0-49149087268 10.1038/onc.2008.114
150. Pedersen P. L., Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect" i.e., elevated glycolysis in the presence of oxygen. Journal of Bioenergetics and Biomembranes 2007 39 3 211 222 2-s2.0-35448964610 10.1007/s10863-007-9094-x
151. Lemasters J. J., Holmuhamedov E., Voltage-dependent anion channel (VDAC) as mitochondrial governator-thinking outside the box. Biochimica et Biophysica Acta 2006 1762 2 181 190 2-s2.0-29344468832 10.1016/j.bbadis.2005.10.006
152. Mailloux R. J., Dumouchel T., Aguer C., Dekemp R., Beanlands R., Harper M.-E., Hexokinase II acts through UCP3 to suppress mitochondrial reactive oxygen species production and maintain aerobic respiration. Biochemical Journal 2011 437 2 301 311 2-s2.0-79959716502 10.1042/BJ20110571
153. Ahn K. J., Kim J., Yun M., Park J. H., Lee J. D., Enzymatic properties of the N-and C-terminal halves of human hexokinase II. BMB Reports 2009 42 6 350 355 2-s2.0-68349143277
154. Majewski N., Nogueira V., Robey R. B., Hay N., Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Molecular and Cellular Biology 2004 24 2 730 740 2-s2.0-0347986675 10.1128/MCB.24.2.730-740.2004
155. Elstrom R. L., Bauer D. E., Buzzai M., Karnauskas R., Harris M. H., Plas D. R., Zhuang H., Cinalli R. M., Alavi A., Rudin C. M., Thompson C. B., Akt stimulates aerobic glycolysis in cancer cells. Cancer Research 2004 64 11 3892 3899 2-s2.0-2542561169 10.1158/0008-5472.CAN-03-2904
156. Pastorino J. G., Hoek J. B., Shulga N., Activation of glycogen synthase kinase 3 β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Research 2005 65 22 10545 10554 2-s2.0-28544436922 10.1158/0008-5472.CAN-05-1925
157. Martel C., Allouche M., Esposti D. D., GSK3-mediated VDAC phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation. Hepatology 2012 57 1 93 102
158. Neary C. L., Pastorino J. G., Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells. Journal of Cellular Physiology 2013 228 9 1943 1948
159. Pastorino J. G., Hoek J. B., Hexokinase II: the integration of energy metabolism and control of apoptosis. Current Medicinal Chemistry 2003 10 16 1535 1551 2-s2.0-0041309460
160. Mathupala S. P., Ko Y. H., Pedersen P. L., Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006 25 34 4777 4786 2-s2.0-33746924468 10.1038/sj.onc.1209603
161. Zorov D. B., Juhaszova M., Yaniv Y., Nuss H. B., Wang S., Sollott S. J., Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovascular Research 2009 83 2 213 225 2-s2.0-67650245365 10.1093/cvr/cvp151
162. Kroemer G., Pouyssegur J., Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008 13 6 472 482 2-s2.0-44449147036 10.1016/j.ccr.2008.05.005
163. Fulda S., Galluzzi L., Kroemer G., Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery 2010 9 6 447 464 2-s2.0-77953131908 10.1038/nrd3137
164. Wolf A., Agnihotri S., Micallef J., Mukherjee J., Sabha N., Cairns R., Hawkins C., Guha A., Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. Journal of Experimental Medicine 2011 208 2 313 326 2-s2.0-79951699777 10.1084/jem.20101470
165. Cheung E. C., Ludwig R. L., Vousden K. H., Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proceedings of the National Academy of Sciences 2012 109 50 20491 20496
166. Simons A. L., Ahmad I. M., Mattson D. M., Dornfeld K. J., Spitz D. R., 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Research 2007 67 7 3364 3370 2-s2.0-34248142302 10.1158/0008-5472.CAN-06-3717
167. Ihrlund L. S., Hernlund E., Khan O., Shoshan M. C., 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology 2008 2 1 94 101 2-s2.0-43649097186 10.1016/j.molonc.2008.01.003
168. Kim W., Yoon J.-H., Jeong J.-M., Cheon G.-J., Lee T.-S., Yang J.-I., Park S.-C., Lee H.-S., Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Molecular Cancer Therapeutics 2007 6 9 2554 2562 2-s2.0-34748922322 10.1158/1535-7163.MCT-07-0115
169. Chiara F., Castellaro D., Marin O., Petronilli V., Brusilow W. S., Juhaszova M., Sollott S. J., Forte M., Bernardi P., Rasola A., Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS ONE 2008 3 3 2-s2.0-46649106720 10.1371/journal.pone.0001852 e1852
170. Heyfets A., Flescher E., Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Letters 2007 250 2 300 310 2-s2.0-34047168229 10.1016/j.canlet.2006.10.013
171. Thalhamer T., McGrath M. A., Harnett M. M., MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008 47 4 409 414 2-s2.0-43049158204 10.1093/rheumatology/kem297
172. Tamura S., Hanada M., Ohnishi M., Katsura K., Sasaki M., Kobayashi T., Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. European Journal of Biochemistry 2002 269 4 1060 1066 2-s2.0-0036181363 10.1046/j.0014-2956.2002.02754.x
173. Ichijo H., Nishida E., Irie K., Ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y., Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997 275 5296 90 94 2-s2.0-14444281569 10.1126/science.275.5296.90
174. Ip Y. T., Davis R. J., Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Current Opinion in Cell Biology 1998 10 2 205 219 2-s2.0-0032054723 10.1016/S0955-0674(98)80143-9
175. Shi Y., Gaestel M., In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biological Chemistry 2002 383 10 1519 1536 2-s2.0-0036803602 10.1515/BC.2002.173
176. Weisburg J. H., Multidrug resistance in acute myeloid leukemia: potential new therapeutics. Journal of Nuclear Medicine 2008 49 9 1405 1407 2-s2.0-51349109215 10.2967/jnumed.107.050153
177. Trinchieri G., Innate inflammation and cancer: is it time for cancer prevention? F1000 Medicine Reports 2011 3 1, article 11 2-s2.0-79960091029 10.3410/M3-11
178. Dang H. T., Lee H. J., Yoo E. S., Hong J., Bao B., Choi J. S., Jung J. H., New jasmonate analogues as potential anti-inflammatory agents. Bioorganic and Medicinal Chemistry 2008 16 24 10228 10235 2-s2.0-56349144702 10.1016/j.bmc.2008.10.050
179. Lee H.-J., Maeng K., Dang H.-T., Kang G.-J., Ryou C., Jung J. H., Kang H.-K., Prchal J. T., Yoo E.-S., Yoon D., Anti-inflammatory effect of methyl dehydrojasmonate (J2) is mediated by the NF- B pathway. Journal of Molecular Medicine 2011 89 1 83 90 2-s2.0-78651367556 10.1007/s00109-010-0688-0
180. Ohnishi H., Miyahara N., Gelfand E. W., The role of leukotriene B4 in allergic diseases. Allergology International 2008 57 4 291 298 2-s2.0-59549104762 10.2332/allergolint.08-RAI-0019
181. Mugoni V., Santoro M. M., Manipulating redox signaling to block tumor angiogenesis. Research Directions in Tumor Angiogenesis 2013 chapter 3 47 72
182. Nguyen D. X., Bos P. D., Massagué J., Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer 2009 9 4 274 284 2-s2.0-63049090100 10.1038/nrc2622
183. Jin Y., Penning T. M., Aldo-keto reductases and bioactivation/ detoxication. Annual Review of Pharmacology and Toxicology 2007 47 263 292 2-s2.0-33847021147 10.1146/annurev.pharmtox.47.120505.105337
184. Matsuura K., Shiraishi H., Hara A., Sato K., Deyashiki Y., Ninomiya M., Sakai S., Identification of a principal mRNA species for human 3 α -hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. Journal of Biochemistry 1998 124 5 940 946 2-s2.0-0031759084
185. Penning T. M., Drury J. E., Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Archives of Biochemistry and Biophysics 2007 464 2 241 250 2-s2.0-34547692874 10.1016/j.abb.2007.04.024
186. Matsunaga T., Wada Y., Endo S., Soda M., El-Kabbani O., Hara A., Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers. Frontiers in Pharmacology 2012 3, article 5
187. Hsu N.-Y., Ho H.-C., Chow K.-C., Lin T.-Y., Shih C.-S., Wang L.-S., Tsai C.-M., Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Research 2001 61 6 2727 2731 2-s2.0-0035866794
188. Vihko P., Herrala A., Härkönen P., Isomaa V., Kaija H., Kurkela R., Li Y., Patrikainen L., Pulkka A., Soronen P., Törn S., Enzymes as modulators in malignant transformation. Journal of Steroid Biochemistry and Molecular Biology 2005 93 2-5 277 283 2-s2.0-20944450263 10.1016/j.jsbmb.2005. 01.002
189. Tai H.-L., Lin T.-S., Huang H.-H., Lin T.-Y., Chou M.-C., Chiou S.-H., Chow K.-C., Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncology Reports 2007 17 2 305 311 2-s2.0-33947713276
190. Deng H. B., Parekh H. K., Chow K.-C., Simpkins H., Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. The Journal of Biological Chemistry 2002 277 17 15035 15043 2-s2.0-0037177887 10.1074/jbc.M112028200
191. Chen Y.-J., Yuan C.-C., Chow K.-C., Wang P.-H., Lai C.-R., Yen M.-S., Wang L.-S., Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecologic Oncology 2005 97 1 110 117 2-s2.0-15544379141 10.1016/j.ygyno.2004.12.031
192. Chen W. D., Zhang Y., Regulation of aldo-keto reductases in human diseases. Frontiers in Pharmacology 2012 3, article 35
193. Ax W., Soldan M., Koch L., Maser E., Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochemical Pharmacology 2000 59 3 293 300 2-s2.0-0033988708 10.1016/S0006-2952(99)00322-6
194. Lee E. K., Regenold W. T., Shapiro P., Inhibition of aldose reductase enhances Hela cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-Cancer Drugs 2002 13 8 859 868 2-s2.0-0036746965 10.1097/00001813-200209000-00012
195. Maccarrone M., Lipoxygenases, apoptosis, and the role of antioxidants. Photoprotection, Photoinhibition, Gene Regulation, and Environment 2008 21 321 332 Advances in Photosynthesis and Respiration
196. Brash A. R., Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. The Journal of Biological Chemistry 1999 274 34 23679 23682 2-s2.0-0033588022 10.1074/jbc.274.34.23679
197. Meyer M. C., Rastogi P., Beckett C. S., McHowat J., Phospholipase A2 inhibitors as potential anti-inflammatory agents. Current Pharmaceutical Design 2005 11 10 1301 1312 2-s2.0-16244389350 10.2174/1381612053507521
198. Bosma-den Boer M. M., van Wetten M.-L., Pruimboom L., Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recovering. Nutrition & Metabolism 2012 9, article 32 2-s2.0-84859738661 10.1186/1743-7075-9-32
199. Werz O., Klemm J., Samuelsson B., Rådmark O., 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proceedings of the National Academy of Sciences of the United States of America 2000 97 10 5261 5266 2-s2.0-0034625136 10.1073/pnas.050588997
200. Tong W.-G., Ding X.-Z., Witt R. C., Adrian T. E., Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapeutics 2002 1 11 929 935 2-s2.0-0036728051
201. Tong W.-G., Ding X.-Z., Adrian T. E., The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochemical and Biophysical Research Communications 2002 296 4 942 948 2-s2.0-0036384212 10.1016/S0006-291X(02)02014-4
202. Ye Y.-N., Liu E. S.-L., Shin V. Y., Wu W. K.-K., Cho C.-H., Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004 203 1-3 179 188 2-s2.0-4444354992 10.1016/j.tox.2004.06.004
203. Tong W.-G., Ding X.-Z., Talamonti M. S., Bell R. H., Adrian T. E., LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochemical and Biophysical Research Communications 2005 335 3 949 956 2-s2.0-23944483974 10.1016/j.bbrc.2005.07.166
204. Ghosh J., Myers C. E., Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochemical and Biophysical Research Communications 1997 235 2 418 423 2-s2.0-0031577170 10.1006/bbrc.1997.6799
205. O'Flaherty J. T., Rogers L. C., Chadwell B. A., Owen J. S., Rao A., Cramer S. D., Daniel L. W., 5(S)-hydroxy-6,8,11,14-E,Z,Z,Z-eicosatetraenoate stimulates PC3 cell signaling and growth by a receptor-dependent mechanism. Cancer Research 2002 62 23 6817 6819 2-s2.0-0036896107
206. Ye Y.-N., Liu E. S.-L., Shin V. Y., Wu W. K.-K., Cho C.-H., Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004 203 1-3 179 188 2-s2.0-4444354992 10.1016/j.tox.2004.06.004
207. Anderson K. M., Seed T., Vos M., Mulshine J., Meng J., Alrefai W., Ou D., Harris J. E., 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998 37 3 161 173
208. Avis I., Hong S. H., Martinez A., Moody T., Choi Y. H., Trepel J., Das R., Jett M., Mulshine J. L., Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. The FASEB Journal 2001 15 11 2007 2009 2-s2.0-0035458615
209. Fan X. M., Tu S. P., Lam S. K., Wang W. P., Wu J., Wong W. M., Yuen M. F., Lin M. C. M., Kung H. F., Wong B. C.-Y., Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. Journal of Gastroenterology and Hepatology 2004 19 1 31 37 2-s2.0-9144224191 10.1111/j.1440-1746.2004.03194.x
210. Kovarikova M., Hofmanova J., Soucek K., Kozubik A., The effects of TNF-alpha and inhibitors of arachidonic acid metabolism on human colon HT-29 cells depend on differentiation status. Differentiation 2004 72 1 23 31
211. Hoque A., Lippman S. M., Wu T.-T., Xu Y., Liang Z. D., Swisher S., Zhang H., Cao L., Ajani J. A., Xu X.-C., Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005 26 4 785 791 2-s2.0-20244363504 10.1093/carcin/bgi026
212. Chen X., Sood S., Yang C. S., Li N., Sun Z., Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention. Current Cancer Drug Targets 2006 6 7 613 622 2-s2.0-33750614657 10.2174/156800906778742451
213. Gupta S., Strivastva M., Ahmad N., Sakamoto K., Bostwick D. G., Muktar H., Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001 91 737 743
214. Yoshimura R., Matsuyama M., Tsuchida K., Kawahito Y., Sano H., Nakatani T., Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. Journal of Urology 2003 170 5 1994 1999 2-s2.0-0141988847 10.1097/01.ju.0000080296.54262.c8
215. Zhi H., Zhang J., Hu G., Lu J., Wang X., Zhou C., Wu M., Liu Z., The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. International Journal of Cancer 2003 106 3 327 333 2-s2.0-0038167016 10.1002/ijc.11225
216. Hennig R., Ding X.-Z., Tong W.-G., Schneider M. B., Standop J., Friess H., Büchler M. W., Pour P. M., Adrian T. E., 5-Lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. American Journal of Pathology 2002 161 2 421 428 2-s2.0-0036971423
217. Zou L.-Y., Li J.-Y., Chen F.-L., Chen Z.-X., Wang X.-Z., Tumor 5-lipoxygenase expression correlates with gastric cancer metastasis and its selective inhibitor induces cancer cell apoptosis. Journal of Cancer Molecules 2006 2 6 227 233
218. Romano M., Catalano A., Nutini M., D'Urbano E., Crescenzi C., Claria J., Libner R., Davi G., Procopio A., 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. The FASEB Journal 2001 15 13 2326 2336 2-s2.0-0035162355 10.1096/fj.01-0150com
219. Avis I. M., Jett M., Boyle T., Vos M. D., Moody T., Treston A. M., Martínez A., Mulshine J. L., Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. The Journal of Clinical Investigation 1996 97 3 806 813 2-s2.0-0030023776
220. Boado R. J., Pardridge W. M., Vinters H. V., Black K. L., Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proceedings of the National Academy of Sciences of the United States of America 1992 89 19 9044 9048 2-s2.0-0026702580 10.1073/pnas.89.19.9044
221. Rao C. V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., Reddy B. S., Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti- inflammatory agent. Cancer Research 1995 55 7 1464 1472 2-s2.0-0028904461
222. Xu X.-M., Deng J.-J., Yuan G.-J., Yang F., Guo H.-T., Xiang M., Ge W., Wu Y.-G., 5-Lipoxygenase contributes to the progression of hepatocellular carcinoma. Molecular Medicine Reports 2011 4 6 1195 1200 2-s2.0-80053110423 10.3892/mmr.2011.547
223. Sveinbjörnsson B., Rasmuson A., Baryawno N., Wan M., Pettersen I., Ponthan F., Orrego A., Haeggström J. Z., Johnsen J. I., Kogner P., Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. The FASEB Journal 2008 22 10 3525 3536 2-s2.0-54049153617 10.1096/fj.07-103457
224. Soumaoro L. T., Iida S., Uetake H., Ishiguro M., Takagi Y., Higuchi T., Yasuno M., Enomoto M., Sugihara K., Expression of 5-lipoxygenase in human colorectal cancer. World Journal of Gastroenterology 2006 12 39 6355 6360 2-s2.0-33750813875
225. Ishii K., Zaitsu M., Yonemitsu N., Kan Y., Hamasaki Y., Matsuo M., 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clinical Neuropathology 2009 28 6 445 452 2-s2.0-70549103224
226. Boger P. C., Shutt J. D., Neale J. R., Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. Histopathology 2012 61 509 517
227. Sun Z., Sood S., Li N., Ramji D., Yang P., Newman R. A., Yang C. S., Chen X., Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 2006 27 9 1902 1908 2-s2.0-33747875667 10.1093/carcin/bgl039
228. Goupil R. C., Bushey J. J., Peters-Kennedy J., Wakshlag J. J., Prevalence of 5-lipoxygenase expression in canine osteosarcoma and the effects of a dual 5-lipoxygenase/cyclooxygenase inhibitor on osteosarcoma cells in vitro and in vivo. Veterinary Pathology 2012 49 5 802 810
229. Hussey H. J., Tisdale M. J., Inhibition of tumour growth by lipoxygenase inhibitors. British Journal of Cancer 1996 74 5 683 687 2-s2.0-0029740056
230. Ding X.-Z., Iversen P., Cluck M. W., Knezetic J. A., Adrian T. E., Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochemical and Biophysical Research Communications 1999 261 1 218 223 2-s2.0-0033595140 10.1006/bbrc.1999.1012
231. Fischer A. S., Metzner J., Steinbrink S. D., Ulrich S., Angioni C., Geisslinger G., Steinhilber D., Maier T. J., 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. British Journal of Pharmacology 2010 161 4 936 949 2-s2.0-77957240474 10.1111/j.1476-5381.2010. 00915.x
232. Ghosh J., Myers C. E., Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998 95 22 13182 13187 2-s2.0-0032573175 10.1073/pnas.95.22.13182
233. Miller T. A., Ghosh J., Myers C. E., Macdonald T. L., 5-HETE congeners as modulators of cell proliferation. Bioorganic and Medicinal Chemistry Letters 2000 10 17 1913 1916 2-s2.0-0034605252 10.1016/S0960-894X(00)00370-X
234. Ghosh J., Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochemical and Biophysical Research Communications 2003 307 2 342 349 2-s2.0-0038013796 10.1016/S0006-291X(03)01201-4
235. Maccarrone M., Melino G., Finazzi-Agrò A., Lipoxygenases and their involvement in programmed cell death. Cell Death and Differentiation 2001 8 8 776 784 2-s2.0-0034904380 10.1038/sj.cdd.4400908
236. Luo M., Lee S., Brock T. G., Leukotriene synthesis by epithelial cells. Histology and Histopathology 2003 18 2 587 595 2-s2.0-0037378120
237. Hanaka H., Shimizu T., Izumi T., Stress-induced nuclear export of 5-lipoxygenase. Biochemical and Biophysical Research Communications 2005 338 1 111 116 2-s2.0-27544516027 10.1016/j.bbrc.2005.09.001
238. Werz O., Steinhilber D., Therapeutic options for 5-lipoxygenase inhibitors. Pharmacology and Therapeutics 2006 112 3 701 718 2-s2.0-33750102847 10.1016/j.pharmthera.2006.05.009
239. Fischer A. S., Metzner J., Steinbrink S. D., Ulrich S., Angioni C., Geisslinger G., Steinhilber D., Maier T. J., 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. British Journal of Pharmacology 2010 161 4 936 949 2-s2.0-77957240474 10.1111/j.1476-5381.2010. 00915.x
240. Bair A. M., Turman M. V., Vaine C. A., Panettieri R. A., Soberman R. J. Jr., The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer. Molecular Biology of the Cell 2012 23 22 4456 4464
241. Russo A., Espinoza C. L., Caggia S., A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells. Cancer Letters 2012 326 2 199 205
242. Marnett L. J., Inflammation and cancer: chemical approaches to mechanisms, imaging, and treatment. The Journal of Organic Chemistry 2012 77 12 5224 5238
243. Pratheeshkumar P., Sreekala C., Zhang Z., Cancer prevention with promising natural products: mechanisms of action and molecular targets. Anti-Cancer Agents in Medicinal Chemistry 2012 12 10 1159 1184
244. Kwak E. L., Clark J. W., Chabner B., Targeted agents: the rules of combination. Clinical Cancer Research 2007 13 18 5232 5237 2-s2.0-34848871080 10.1158/1078-0432.CCR-07-1385
245. Ghavami G., Kazemali M. R., Sardari S., Informatics of drug synergism in naturally occurring anticancer agents. Recent Patents on Anti-Cancer Drug Discovery 2011 6 1 26 44 2-s2.0-78650934857 10.2174/157489211793980105
246. Mohan A., Narayanan S., Sethuraman S., Krishnan U. M., Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy. Anti-Cancer Agents in Medicinal Chemistry 2013 13 2 281 295
247. Takimoto R., Kato J., Terui T., Takada K., Kuroiwa G., Wu J., Ohnuma H., Takahari D., Kobune M., Sato Y., Takayama T., Matsunaga T., Niitsu Y., Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. Cancer Biology and Therapy 2005 4 4 421 428 2-s2.0-25144441207
248. Vinod B. S., Maliekal T. T., Anto R. J., Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxidants & Redox Signaling 2013 18 11 1307 1348
249. Cai S., Xu Y., Cooper R. J., Ferkowiez M. J., Hartwell J. R., Pollok K. E., Kelley M. R., Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Research 2005 65 8 3319 3327 2-s2.0-17144431814
250. Tsang W. P., Chau S. P. Y., Kong S. K., Fung K. P., Kwok T. T., Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sciences 2003 73 16 2047 2058 2-s2.0-0042705073 10.1016/S0024-3205(03)00566-6
251. Yeruva L., Hall C., Elegbede J. A., Carper S. W., Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. Anti-Cancer Drugs 2010 21 1 1 9 2-s2.0-74349110044 10.1097/CAD.0b013e32832a68ad
252. Macciò A., Madeddu C., Cisplatin: an old drug with a newfound efficacy-from mechanisms of action to cytotoxicity. Expert Opinion on Pharmacotherapy 2013 14 13 1839 1857 10.1517/14656566.2013.813934
253. Farooqi A. A., Butt G., Razzaq Z., Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of 'the dance macabre'. Cancer Cell International 2012 12, article 50
254. Xiao X.-Y., Jiang G.-S., Wang L., Lv L., Zeng F.-Q., Predominant enhancement of apoptosis induced by methyl jasmonate in bladder cancer cells: therapeutic effect of the Antp-conjugated Smac peptide. Anti-Cancer Drugs 2011 22 9 853 863 2-s2.0-80052469706 10.1097/CAD.0b013e3283482d40
255. Jiang G., Zhao J., Xiao X., Tao D., Gu C., Tong Q., Luo B., Wang L., Zeng F., AN N-terminal Smac peptide sensitizes human prostate carcinoma cells to methyl jasmonate-induced apoptosis. Cancer Letters 2011 302 1 37 46 2-s2.0-79251600082 10.1016/j.canlet.2010.12.009
256. Hernandes C. C. G., França S. C., Fachin A. L., Marins M., Lourenço M. V., Cytotoxic effect of jasmonate and methyl jasmonate on a canine macrophage tumor cell line. A Revista Brasileira de Plantas Medicinais 2012 14 1 122 124